BTG International Limited (2004) Treatment of neurodegenerative conditions. US 2004/0229873 Al.

Preview

PDF (United States Patent Application Publication) US2004229873A1.pdf Available under License Creative Commons Attribution No Derivatives. Download (340kB)

Abstract

A method of treating a patient in need of therapy for multiple sclerosis is provided, comprising administering to that patient a therapeutically effective dose of a compound of formula I during periods of remission, as well as during relapse, wherein R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, trihaloalkyl and halo substituents; X1, X2 and X3 are independently selected from the group consisting of CH, CCH2F, CCF3, COalkyl and CCH3, and nitrogen atoms, with at two of X1, X2 and X3 being nitrogen; and Y1 and Y2 are independently selected from the group consisting of hydrogen and primary, secondary and tertiary amino groups.
Preferred compounds of formula 1 is selected from the group consisting of Lamotrigine, Sipatrigine, 4030w92, 202w92, 78c90 (active Sipatrigine metabolite), 440c89, 149C89, 722c90, 279c90 and 1003c87.
The therapy results in reduction of one or more of incidence of relapse, spasticity and fatigue and exceptionally the therapy stabilises the patients Expanded Disability Status Score (EDSS), thus halting progress of the disease.

Item Type:	Patent
Additional Information:	Publication Number: US 2004/0229873 Al Publication Date: Nov. 18, 2004 Application Number: 10/756,761 Filed: Jan. 14, 2004
Uncontrolled Keywords:	lamotrigine, multiple sclerosis, use patent
Subjects:	Q Science > QD Chemistry R Medicine > RS Pharmacy and materia medica
Faculty / School / Research Centre / Research Group:	Faculty of Education, Health & Human Sciences > School of Human Sciences (HUM)
Related URLs:	Organisation
Last Modified:	09 Oct 2021 04:46
URI:	http://gala.gre.ac.uk/id/eprint/4323

Actions (login required)

View Item

Downloads